Exonate
Ken is Head of Biology for Exonate‘s ophthalmology programme and joined us in April 2017. He is responsible for managing the team on a day to day basis and bridging the gap between the R&D team and the management team. Ken was previously Associate Director at AstraZeneca for 11 years and spent 4 years as a senior lecturer in Pharmacy.
Exonate
Exonate is a biotech company spun out of the University of Nottingham that is focused on alternative splicing of (VEGF) in ophthalmology.